Your browser doesn't support javascript.
Intravenous vitamin C use and risk of severity and mortality in COVID-19: A systematic review and meta-analysis.
Ao, Guangyu; Li, Jing; Yuan, Yang; Wang, Yushu; Nasr, Basma; Bao, Mulong; Gao, Ming; Qi, Xin.
  • Ao G; Department of Nephrology, Chengdu First People's Hospital, Chengdu, Sichuan, China.
  • Li J; Department of Nephrology, Chengdu First People's Hospital, Chengdu, Sichuan, China.
  • Yuan Y; Department of Minimally Invasive Surgery-Hepatobiliary and Pancreatic Surgery Thoracic Surgery, West China Fourth Hospital, Sichuan University, Sichuan, China.
  • Wang Y; Chengdu West China Clinical Research Center CO, Ltd, Sichuan, China.
  • Nasr B; Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, China.
  • Bao M; Department of Intensive Care Unit, Chengdu First People's Hospital, Chengdu, Sichuan, China.
  • Gao M; Department of Cardiology, Chengdu First People's Hospital, Chengdu, Sichuan, China.
  • Qi X; Department of Neurology, The Affiliated Hospital of Southwest Jiaotong University & The Third People's Hospital of Chengdu, Chengdu, Sichuan, China.
Nutr Clin Pract ; 37(2): 274-281, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1680518
ABSTRACT
The administration of intravenous vitamin C (IV-VC) in treating patients with coronavirus disease 2019 (COVID-19) is still highly controversial. There have been no previous studies on the effect of IV-VC on the severity and mortality of COVID-19. Hence, we conducted a systematic review and meta-analysis to compare the disease severity and mortality in patients with COVID-19 who promptly received IV-VC treatment vs those who did not. We performed a comprehensive systematic search of seven health science databases, including PubMed, Embase, Cochrane Library, MEDLINE, Web of Science, China National Knowledge Infrastructure, and Wanfang Data, up to June 23, 2021. We identified a total of seven related articles, which were included in this study. This meta-analysis showed that IV-VC treatment did not affect disease severity compared with placebo treatment or usual care (odds ratio [OR], 0.70; 95% CI, 0.45 to 1.07; P = 0.10). In addition, no statistically significant difference in mortality was observed between patients who received IV-VC treatment and those who did not (OR, 0.64; 95% CI, 0.41 to 1.00; P = 0.05). Moreover, the adjusted meta-analysis revealed that the use of IV-VC did not influence disease severity (OR, 0.67; 95% CI, 0.34 to 1.31; P = 0.242) or mortality (OR, 1.02; 95% CI, 0.75 to 1.40; P = 0.877) in comparison with a control group. The results of this meta-analysis demonstrated that short-term IV-VC treatment did not reduce the risk of severity and mortality in patients with COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans Country/Region as subject: Asia Language: English Journal: Nutr Clin Pract Journal subject: Nutritional Sciences / Nursing Year: 2022 Document Type: Article Affiliation country: Ncp.10832

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans Country/Region as subject: Asia Language: English Journal: Nutr Clin Pract Journal subject: Nutritional Sciences / Nursing Year: 2022 Document Type: Article Affiliation country: Ncp.10832